Another approach is to develop less toxic agents targeting cancer specific pathways (Ras, MEK, ERK, PI3K, IGF-1 and insulin, ErbB and other growth factors receptors, AMPK, mTOR, p70 S6 kinase, p53, oncogenic metabolism [] [228, 253-259]. This evidence concerns the gene TP53 and cancer.